1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

Mineralys Is In A Close Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Mineralys Therapeutics
Mineralys Therapeutics (Shutterstock)

Mineralys’s lorundrostat has demonstrated its potential to reduce blood pressure in patients with hypertension again, as the aldosterone synthase inhibitor has achieved a third clinical win in recent months giving close fight to AstraZeneca’s baxdrostat.

Key Takeaways
  • Lorundrostat met key efficacy and safety endpoints in the Phase II Explore-CKD trial, showing blood pressure and kidney benefits. 

      The biotech firm has announced positive topline data from its Phase II Explore-CKD trial evaluating the safety and efficacy of...

      Read the full article – start your free trial today!

      Join thousands of industry professionals who rely on Scrip for daily insights

      • Start your 7-day free trial
      • Explore trusted news, analysis, and insights
      • Access comprehensive global coverage
      • Enjoy instant access – no credit card required
      Start Free Trial

      Already a subscriber?

      More from Clinical Trials

      Capricor Gets Complete Response For DMD Cell Therapy

       
      • By Joseph Haas

      Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

      Bayer Bags First Global Okay For Hot Flashes Therapy

       
      • By Kevin Grogan

      Lynkuet will compete with Astellas's Veozah/Veoza

      Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

       
      • By Anju Ghangurde

      Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

      Four Chinese Firms Snag Global First-In-Class Approvals In China

       
      • By Dexter Jie Yan

      Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

      More from Therapy Areas

      AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

       
      • By Alaric DeArment

      IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

      Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

       
      • By Kevin Grogan

      The osteogenesis imperfecta drug stumbled in a second interim analysis.

      Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

       
      • By Andrew McConaghie

      The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.